Scientific deep-dive
GLP-1 Drugs After Menopause: The Group Taking Them Most, Studied Least
One review exists on GLP-1 drugs in peri- and postmenopausal women, and it opens by describing a paucity of data. This sets out what has to be borrowed from other populations, and which borrowings hold up.
These drugs work in menopausal women. They are the most effective weight-loss medicines available for essentially every population studied, and there is no reason to think this one is the exception.[1] What there is almost none of is evidence about this population specifically. The review that exists to summarize it opens by describing a paucity of data. So this page is less a set of findings than an account of what has to be borrowed from elsewhere, and which of those borrowings hold up.
Why the weight arrived in the first place
Weight gain through the menopausal transition is not simply eating more. Falling estrogen shifts where fat is stored, toward the abdomen; lean muscle declines with age independently of that; sleep gets worse, and poor sleep changes appetite regulation. The result is a body that needs fewer calories while wanting the same amount of food, and it is a different problem from weight gained at thirty.
A GLP-1 addresses one part of that, the appetite side, and does it well. It does nothing about estrogen, and it is not a treatment for menopause. Whether hormone therapy belongs in the picture alongside it is a question for a clinician who knows your history; our ranking of online hormone therapy providers covers the practices that prescribe it. The GLP-1 trials were not built to address it.
What the menopause-specific literature says
One review, published in 2025 in Current Opinion in Obstetrics and Gynecology, set out to gather what is known about GLP-1 drugs in peri- and postmenopausal women.[1] Its conclusion is that they are consistently the most effective drug class for weight loss and a valuable tool in this group, and that more research is needed to establish the risks, the benefits and the right way to use them here.
Bone, and a borrowing that does not quite work
This is the risk that matters more after menopause than before it, because estrogen withdrawal accelerates bone loss and rapid weight loss costs bone density on its own. Stack the two and the question is real.
The available evidence is a 2025 meta-analysis of 25 studies, and it is reassuring: no significant association with increased fracture risk (relative risk 0.80, 95% CI 0.47 to 1.36), a statistically significant improvement in lumbar spine bone mineral density, and improvements in several bone turnover markers.[2]
All 25 studies were in type 2 diabetes, and none was a study of bone loss after menopause.
That is a serious limitation. Bone loss in type 2 diabetes and bone loss after menopause are different processes with different drivers, and a null result in one is weak evidence about the other. The finding is encouraging and it is the best available, but it is not the study anyone would design to answer this question, and its own authors call for longer follow-up before drawing firm conclusions.[2]
In practice, if you have osteopenia, osteoporosis, a previous fragility fracture or a family history of one, that belongs in the conversation before the first injection rather than after a year of rapid loss. So does whether anyone is measuring your bone density at all.
Muscle, where the same number means something different
A 2026 pooled analysis of 20 randomized trials in 15,782 people put lean mass at between 25% and 35% of the weight lost on these drugs, depending on which one, and found intensive lifestyle programs costing 26%, inside that range.[3] Losing some lean tissue is what losing weight does, not something these drugs do to you. Our lean mass and hair loss article works through that in full.
Lean-mass loss still belongs on this page, because the same percentage lands on a different starting point. Muscle mass declines with age regardless, and the decline steepens around menopause. A quarter of a large weight loss coming from lean tissue is one thing at thirty-five with a full reserve, and another at fifty-eight with less of it and less capacity to rebuild.
Nothing in the trials tells you how much that matters for you. The best-supported countermeasure is resistance training and enough protein, from the beginning rather than after the loss.[3] Our protein calculator works a target from body weight, and the exercise pairing tool sets out what the training side looks like.
The things nobody has measured here
- Interaction with hormone therapy. No completed trial has reported on it. One registered trial of the combination in postmenopausal women (NCT06715514) is still under way. That does not imply a problem; it means there is no result yet, and your prescriber is reasoning from first principles too.
- Effects on menopausal symptoms. Weight loss can change hot flashes, sleep and mood, and no trial of these drugs measured them in this population. The same gap covers vaginal dryness, set out in GLP-1 drugs and vaginal symptoms, and bleeding after menopause is never a side effect to wait out (GLP-1 drugs and your period).
- Bone outcomes after menopause specifically. The reassuring fracture data come from people with type 2 diabetes.[2]
- What happens over a decade. The trials run one to two years. Postmenopausal life runs several decades.
Frequently Asked Questions
References
- 1.Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence Current Opinion in Obstetrics and Gynecology. 2025. PMID: 39970049.
- 2.Tan Y, Liu S, Tang Q. Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis Acta Diabetologica. 2025. PMID: 39985672.
- 3.Eisa N, Barood O. Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta-Analysis of Randomised Controlled Trials Diabetes, Obesity and Metabolism. 2026. PMID: 41877354.
Compare the sellers
Related research
GLP-1 Drugs and Quitting Smoking: What the Trials Actually Tested
The largest randomized trial found a GLP-1 added nothing to quit rates (63% against 65% on placebo) while holding post-cessation weight for as long as it was taken. A year later that advantage had gone too.
7 min read
Amycretin: A 24% Weight Figure, and the Trial It Came From
Once-weekly amycretin produced an estimated 24.3% bodyweight reduction at 36 weeks against 1.1% on placebo. It came from a single-site phase 1b/2a study of 125 people whose primary endpoint was counting adverse events.
5 min read
GLP-1 Drugs and Headache: A Side Effect, and a Treatment
Headache is in the label’s adverse reactions table at 14% against 10% on placebo. A randomized trial using implanted pressure monitors also found a GLP-1 lowered intracranial pressure within hours.
7 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
GLP-1 Drugs and Eating Disorders: Two Questions, One Studied
Five studies covering 182 people make up the whole meta-analytic evidence base in binge eating disorder. What happens when these drugs reach someone with a restrictive eating disorder has never been studied at all.
6 min read
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.
7 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
WellMedRx
Comparing compounded and brand GLP-1 plans with a published state list
From $49/mo
Get started →altRX
Compounded semaglutide from $89/month at the same price at every dose
From $89/mo
Get started →CoreAge Rx
Flat-priced compounded semaglutide at $79 a month, any dose
From $79/mo
Get started →